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Why kidney injury is sometimes repaired with complete
restoration of its structural features, whereas in other in-
stances it leaves behind tubular atrophy and interstitial
fibrosis, is a conundrum. There is also considerable con-
troversy regarding the primacy of tubular or interstitial
factors in renal disease progression. As recently editori-
alized in this journal by Cook,1 there is a need for further
research in this area, but carefully performed morpholog-
ical studies show that tubular pathological characteristics
precede interstitial fibrosis in most of the renal diseases;
he suggests that fibrosis does not proceed autono-
mously. The implication is that continuing tubular dam-
age is needed to drive the disease progression, culmi-
nating in fibrosis. In a given glomerular disease, tubular
damage occurs secondarily in the same nephron and
fibrosis develops only around the atrophic tubules.2 By
using models of tubular injury caused by ischemia or
selective ATP depletion by maleate, Geng et al3 and Lan
et al4 strengthened the case for the primacy of tubular-
based factors in the progression of renal fibrosis. Simi-
larly, Grgic et al5 used a transgenic approach in mice to
elucidate that interstitial fibrosis follows selective damage
to proximal tubular cells. Regardless, the precise tubular-
based factors that cause fibrosis remain to be identified.
Autocrine TGF- Signaling by Tubules
Causes Fibrosis in the Injured Kidney
In response to injury, kidney tubules increase synthesis of
transforming growth factor- (TGF-), a profibrogenic cy-
tokine. Spurgeon et al6 observed that, after ischemia-
reperfusion injury (IRI), regenerating proximal tubules ex-
press more TGF- and TGF- receptors, suggesting that
the mechanisms related to increased autocrine TGF-
signaling may be operative. Interestingly, neutralizing
TGF- antibodies prevented IRI-initiated kidney fibrosis.6Along these lines, Geng et al3 further emphasized therole played by TGF-–induced dedifferentiation of tu-
bules in fibrosis after IRI, and they showed that inhibition
of TGF- signaling effectively promotes tubular epithelial
differentiation, prevents tubular atrophy, and reduces in-
terstitial fibrosis. The phenotype of TGF-–induced ded-
ifferentiated tubules was defined by Lan et al,4 who sug-
gested that atrophic tubules that evolve after IRI show
persistent dedifferentiation, depleted phosphatase and
tensin homolog protein with growth arrest, accentuated
signaling by Jun N-terminal kinase, and increased ex-
pression of profibrogenic peptides [ie, platelet-derived
growth factor-B (PDGF-B) chain and connective tissue
growth factor (CTGF)]. The entire spectrum of complex
pathological characteristics affecting this dysfunctional
tubular phenotype was ameliorated by prior inhibition of
TGF- signaling.3,4 Likewise, Yang et al7 noted an aber-
rant persistence of Jun N-terminal kinase signaling and
production of TGF- and CTGF by growth-arrested tubu-
lar cells associated with interstitial fibrosis that ensued
after IRI. On the other hand, it is still unclear how TGF-
signaling becomes accentuated in tubules of an injured
kidney, which then generates fibrogenic signals or ef-
fects.
A Winding Road from GPCRs to TGF-
Activation and Profibrogenic Peptide
Secretion by Tubular Cells
In this issue of The American Journal of Pathology, Venka-
tachalam and colleagues8 demonstrate the operation of
an intricate signaling mechanism in proximal tubular cells
that involves the activation of G-protein–coupled recep-
tors (GPCRs) by lysophosphatidic acid (LPA) and sub-
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TGF- to active peptide. These actions of LPA require
LPA2 receptors and Gq signaling, channeled via a Rho/
Rho-associated kinase pathway. The nascent TGF- pro-
duced by this mechanism initiates autocrine signaling
that triggers the synthesis and secretion of additional
profibrogenic peptides, PDGF-B and CTGF.8 The step-
by-step signaling connections between LPA2 receptor
activation and PDGF-B/CTGF secretion in cultured cells
elucidated by these authors could possibly have impor-
tant implications for understanding the pathogenesis of
tubulointerstitial fibrosis. Indeed, their study includes im-
portant in vivo observations that suggest that the new
signaling paradigm for profibrogenic peptide secretion is
relevant to the tubulointerstitial disease process. They
provide solid circumstantial, but tantalizing, data to string
together the LPA2 and v6 integrin to heighten TGF-
signaling and overexpression of PDGF-B and CTGF in
tubules and ensuing fibrosis after IRI. Furthermore, the in
vitro culture system data indicated that the expression of
epithelial-restricted v6 integrin is rapidly increased af-
ter wounding of proximal tubular epithelium and during
the reparative phase of tubular epithelial injury; in addi-
tion, the LPA2 receptor becomes overexpressed in kid-
neys after IRI in a manner that is temporally coincident
with increased TGF- signaling and profibrogenic pep-
tide expression in tubules associated with fibrosis. These
observations should provide impetus to further pursue
research in this field and address certain critical ques-
tions. Does TGF- directly control the production of
PDGF-B and CTGF after a tubular injury in vivo, as the
studies in cultured cells suggest? How is TGF- signaling
regulated in kidney tubules during health and disease? If,
as the authors suggest, there are multiple and possibly
redundant pathways to regulate TGF- signaling in kid-
ney tubules in vivo through GPCRs, what are those cellu-
lar events?
LPA Is One of the Several Possible Ligands
to Activate the GPCR–v6 Integrin–TGF-
Axis
Studies in lung epithelial cells by Jenkins and col-
leagues9,10 have previously demonstrated that LPA and
thrombin engage GPCRs [LPA2 and protease activated
receptor (PAR)-1] to activate signaling via a Gq and
RhoA/Rho-associated kinase pathway that leads to v6
integrin–dependent activation of latent TGF-, steps that
are identical to those reported for kidney epithelium by
Venkatachalam and colleagues.8 Furthermore, these in-
vestigators correlated LPA-mediated TGF- activation
with lung fibrosis and convincingly demonstrated in their
studies the spatial and temporal associations of in-
creased epithelial expression of LPA2 and v6 integrin
in the regions of fibrosis in lungs that were experimentally
injured by bleomycin administration and in human lung
tissue with idiopathic pulmonary fibrosis.10 In addition,
their studies indicated that thrombin stimulates v6 in-
tegrin–mediated activation of TGF- through PAR-1 re-
ceptors and a RhoA/Rho-associated kinase pathway inlungs; they thoroughly documented the dependence of
experimentally induced acute lung injury on v6 integ-
rin– and PAR-1–dependent mechanisms.9 The similarity
of these robust data of experimental and human lung
diseases to those reported by Venkatachalam and col-
leagues is striking.8 The data of these studies are per-
suasive to indicate that the GPCR–v6 integrin–TGF-
signaling axis has an important role to play in diverse
contexts of a fibrotic disease process. Another serum
lipid, sphingosine-1-phosphate, a less well-studied
GPCR ligand that Geng et al8 discovered, was also ca-
pable of triggering TGF- signaling. Thus, the GPCR
signaling that activates TGF- could conceivably have
several signaling inputs in the early stages of the disease,
while making the actual totality of signaling involved a
complex pathobiological process.
The Case for Integrin-Dependent Epithelial
TGF- Activation in Fibrosis
Experimental evidence restricted to integrin-dependent
activation of TGF- is even more substantial than the
detailed and intricate connections between GPCR acti-
vation, v6 integrin, and TGF- signaling, as alluded by
Jenkins et al9; this was further extended by Geng et al8 to
GPCR–v6 integrin–TGF-–dependent production of
PDGF-B and CTGF. Munger et al11 first established v6
integrin–dependent activation of latent TGF- as a major
mechanism for spatially restricted synthesis of active
TGF- on the plasmalemmal surface of pulmonary epi-
thelial cells, and they proposed this to be an underlying
mechanism for experimental lung fibrosis. Interestingly,
they also reported that 6 integrin–null mice exhibit ex-
aggerated inflammation because of the lack of active
TGF-1 production but were protected from the develop-
ment of fibrosis.11 Similarly, Wang et al12 showed that the
6 integrin–null phenotype conferred protection from
TGF-–mediated hepatic fibrosis after bile duct ligation
without affecting the inflammatory component. Thus, by
eliminating the effects of v6 integrin–dependent
TGF-1 signaling on inflammation versus fibrosis, these
investigators demonstrated that the profibrogenic signals
of TGF-1 generated on epithelial surfaces occur directly
and are independent of intermediary inflammation steps.
Dependency on v6 integrin for TGF-1–mediated
fibrosis has been shown in kidney diseases. Ma et al13
reported that renal fibrosis after unilateral ureteral ob-
struction is decreased in 6 integrin–null mice. Hahm et
al14 described increased v6 integrin expression in re-
nal tubular epithelial cells in a variety of human chronic
kidney diseases associated with fibrosis and in experi-
mental Alport’s syndrome in mice. This increase of v6
integrin has been ascribed to the effects of enhanced
TGF- signaling.14 Conceivably, that would mean that the
increased v6 integrin expression and enhanced active
TGF- production form a self-sustaining loop of positively
reinforced TGF- signaling, and that v6 integrin–neu-
tralizing antibodies may be useful for dampening the
fibrogenic response in chronic kidney diseases.14 Along
these lines, several other integrin species have been
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such integrins, although having activities similar to that of
v6 (ie, mediating the release of active TGF- from
latent precursor through actin cytoskeleton–dependent
conformational changes), operate in mesenchymal cells,
rather than in epithelia.15 One exception may be MDCK
cells, in which v3 has activated TGF-.16 v8 Integrin
also activates TGF-, but via a protease-mediated mech-
anism.15 Thus, v6 integrin, restricted to epithelia, is
uniquely well positioned to respond to signals in a man-
ner alluded to by Jenkins et al9 and Venkatachalam and
colleagues8 for the generation of active TGF-.
Because TGF- Is Profibrogenic, What Is the
Need for Later Steps Involving PDGF-B and
CTGF?
Regardless of the significance of GPCR-v6 integrin
signaling for latent TGF- activation, a plausible mecha-
nism, the findings of Venkatachalam and colleagues8
raise certain other intriguing questions. TGF- acts inde-
pendently profibrogenic because it increases the synthesis
of extracellular matrix while decreasing its degradation,
which potentially is mediated by paracrine stimulation of
pericytes and fibroblast progenitors in the adjacent intersti-
tium. It is intriguing to determine the significance of TGF-–
dependent synthesis and the secretion of two other profi-
brogenic peptides, PDGF-B and CTGF, by proximal
tubule cells in the current scenario. The clues may lie in
the unique and stringently controlled mechanisms by
which unused nascent TGF- becomes rapidly deacti-
vated. After active TGF- is formed on epithelial cell
surfaces by the actions of v6 integrin, ligand binding to
TGF- receptors is followed by endocytosis of the signal-
ing complex and eventual degradation. Unused ligand
left on the plasmalemmal surface is quickly deactivated
by reconversion to latent TGF-, and its bonding with
latent TGF-–binding proteins would likely form large
inactive complexes.11,15,17 The present consensus is that
an entire TGF- activation-deactivation machinery is lo-
cated on the cell surface. This implies that active TGF-,
formed in vivo on proximal tubular cell surfaces by the
v6-mediated mechanism, is available within a short
time frame for binding to its receptors on the same cell or
those present in its immediate vicinity, but not to intersti-
tial cells that lie beyond the barrier of the tubular base-
ment membrane (TBM). Although latent TGF- could dif-
fuse across the TBM, it has to be activated by interstitial
pericytes/fibroblast progenitors if signaling is to be initi-
ated through their receptors. However, it is more likely
that latent TGF- does not exist as such in the extracel-
lular matrix but becomes immobilized through binding to
latent TGF- binding proteins. Therefore, the generation
of active TGF- on proximal tubular cell surfaces in vivo
may be expected to trigger autocrine TGF- signaling
that increases the production of TBM matrix by the same
cells in an autologous manner; this results in thickened
TBMs, a consistently observed pathological feature in
kidneys with increased TGF- signaling, but not in fibro-
sis, as conventionally understood. The latter involves(myo)-fibroblast proliferation in the interstitium and in-
creased expression of types I and III collagens. It is in this
context that TGF-–dependent secretion of PDGF-B and
CTGF by proximal tubular cells becomes pertinent. Both
PDGF-B and CTGF do not require activation or become
deactivated as active TGF- does; therefore, they are
able to diffuse across TBMs and then induce paracrine
stimulation of fibroblast progenitors and pericytes in
the renal interstitium. These considerations do not ex-
clude the possibility of independent activating mecha-
nisms for TGF- signaling by interstitial cells in kidney
disease. However, as previously considered, such pro-
cesses that operate autonomously of tubules are unlikely
to cause kidney fibrosis, except in contexts in which the
primary site of disease initiation is the renal interstitium.1
In sites where tubular damage is primary, a signaling
pathway such as that proposed by Venkatachalam and
colleagues8 is likely to be an initiating step that produces
interstitial pathological characteristics via the generation
of secreted paracrine peptides (PDGF-B and CTGF) that
diffuse across the TBMs into the interstitium. In such a
scenario, the evolution of progressive disease can only
be explained by repetitive or relentless tubular injury that
leads to comparable and parallel repetitive or sustained
signaling stimuli, which ultimately would be a trigger for
ensuing interstitial fibrosis.
Difficulties Ahead
Pandora’s Box Has Too Many Surprises
As attractive as the signaling pathway delineated by Ven-
katachalam and colleagues8 might be, much remains to
be done to place it in the proper context of in vivo disease
process and to establish the importance of this mecha-
nism in the development of fibrosis. This will be difficult in
view of the many variables inherent to the complex sig-
naling steps between LPA ligation of its receptors and the
secretion of PDGF-B/CTGF, and also because of many
potential redundancies with respect to both plausible
GPCR ligands and alternative pathways to activate
TGF-. Geng et al,8 in their article, indicated that angio-
tensin II, sphingosine-1-phosphate, and thrombin are
also candidate ligands for GPCR to exert their biological
effects in acute kidney injury. In this regard, long-term
infusion of angiotensin II has induced renal fibrosis via an
epidermal growth factor receptor–mediated extracellular
signal–regulated kinase–mitogen-associated protein ki-
nase–dependent pathway that increases the TGF- ex-
pression in proximal tubules.18 Whether angiotensin II
increases TGF- signaling by mechanisms similar to
those described by Geng et al8 was not investigated.
Despite these imponderable variables, LPA is a strong
and viable candidate for relevant pathobiological signal-
ing processes in states of kidney injury, including those
settings that are conducive to fibrosis.
LPA is normally present in low concentrations (1 to 5
mol/L) in serum and biological fluids and in higher levels
in damaged tissue.19 Platelet aggregation can occur in
blood circulating through the microcirculation, leading to
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1-phosphate from platelets at the site of tissue injury.
Locally increased LPA in tissue may also be derived as a
metabolic by-product, by which activation of several en-
zymes leads to de novo synthesis and release of LPA. The
renal content of LPA has significantly increased subse-
quent to unilateral ureteral obstruction, which is usually
accompanied by fibrosis. Interestingly, the renal fibrosis
is significantly attenuated in LPA1/ mice,20 suggesting
that LPA1 is involved in obstruction-induced tubulointer-
stitial fibrosis. How this may relate to the signaling para-
digm described by Geng et al8 is unclear.
In summary, first, regardless of obvious merits, the
study by Geng et al8 lacks direct in vivo evidence for
LPA-induced LPA2 receptor–mediated v6 integrin–
dependent latent TGF- activation and PDGF-B/CTGF
secretion as they may relate to kidney fibrosis. Although
the relevance of v6 integrin in kidney fibrosis has been
well described in the ureteral obstruction and Alport’s
syndrome models,13,14 no such evidence exists for the
role of the LPA2 receptor. LPA2 receptor–null mice are
available, and it may be instructive to test whether they
respond to renal injury in a manner that would be mean-
ingful for addressing the questions under discussion.
Second, participation of other latent TGF- activators (eg,
thrombospondin-1 and other integrins) cannot be ex-
cluded in states leading to fibrosis. Third, although Geng
et al8 provide clear-cut evidence for the proposed mech-
anism in cultured cells, the cells targeted by LPA in vivo
need to be identified and the LPA-mediated mechanism
needs to be defined in that appropriate context. Thus, as
is usual for studies that report a new paradigm to explain
complex biological effects, their study generates more
questions than answers. However, the potential ramifica-
tions of the intriguing and complex, but plausible, signal-
ing pathway reported herein should provide impetus for
addressing these challenging questions. Finally, by iden-
tifying LPA as a possible ligand that initiates/propels
TGF- signaling, their study raises an inevitable and mys-
tifying question: given that LPA is ubiquitously present
and, therefore, available to uninjured cells, what is the
injury-related signal that modifies the LPA2 receptor such
that it becomes permissive for LPA-mediated activation?
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